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Treatment of Patients with Both Arrhythmias
and Heart Failure
Patients with heart failure have a high prevalence of arrhythmias. It is diﬃcult to treat
these patients. Heart failure is occasionally exacerbated by class 1a antiarrhythmic drugs,
which suppress arrhythmias in these patients. The prevalence of ventricular arrhythmias is
frequently increased in patients treated with inotropic agents, which improve ventricular
contraction.
In my strategy, patients with heart failure and ventricular arrhythmias are ﬁrst treated
with drugs to improve heart failure. Recently the treatments of chronic heart failure have
progressed to improve the cardiac function and prognosis. In patients treated by
angiotensin-converting enzyme(ACE) inhibitors, angiotensin II receptor antagonists(ARB)
and aldosterone receptor inhibitors the prevalence of ventricular arrhythmias decreased by
10 to 30% in one year. Carvedilol and other beta-blocking agents reduce the risk of sudden
death by 40 percent or more in patients with heart failure. After drug therapy to improve
heart failure, these patients are treated with antiarrhythmic drugs, especially amiodarone,
without negative inotropic eﬀects. In patients with heart failure and sustained ventricular
tachycardia or ﬁbrillation, an implantable cardioverter-diﬁbrillator (ICD) has a favorable
eﬀect on survival. In patients with heart failure, sudden death can be caused not only by
ventricular tachyarrhythmias, but also by bradyarrhythmias. ICD therapy can decrease the
risk of death in patients with ventricular tachyarrhythmias and at the same time in those
with bradyarrhythmias.
Atrial ﬁbrillation is present in 10 to 50% of patients with heart failure. A loss of atrial
contraction and an irregular ventricular ﬁlling time that is associated with atrial ﬁbrillation
may have negative clinical consequences in patients with heart failure. Some data suggest
that ablation of atrial ﬁbrillation can improve ventricular function in patients with abnormal
systolic function. For these reasons, I have tried to restore and maintain sinus rhythm in
patients with atrial ﬁbrillation and heart failure. We expected that such patients with control
of the ventricular rate (rate control) have a worse prognosis than those in whom sinus
rhythm is maintained (rhythm control). AF-CHF trial [N. Engl. J. Med. 358, 2667–2677
(2008)] showed that rhythm control does not reduce the rate of death from cardiovascular
causes, worsening heart failure and stroke, as compared with a rate-control strategy. In this
trial, amiodarone was the drug of choice for the maintenance of sinus rhythm, and beta-
blockers with digilalis for achievement of the targeted heart rate. Both drugs have beneﬁcial
eﬀects for patients with heart failure. I hope to learn of the outcome after excluding the
beneﬁt provided by these two drugs on heart failure.
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